Ipamorelin vs Survodutide
Well Studied vs Extensively Studied
monitor Mechanism-based · 47% Both Ipamorelin and Survodutide affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
Ipamorelin Survodutide
Weight 711.85 Da ~4,500 Da
Half-life ~2 hours Approximately 6 days (109-115 hours)
Chain 5 amino acids 29 amino acids
Type Growth hormone secretagogue Peptide with fatty acid acylation
Key Benefits
Ipamorelin
01 Optimal GH stimulation with superior bioavailability
02 Body composition improvements (lean mass, fat loss)
03 Enhanced recovery and anti-aging effects
04 Minimal side effects compared to other GHRPs
05 No significant cortisol or prolactin elevation
06 Improved sleep quality
Survodutide
01 Superior weight loss vs monotherapy (14.9% at 46 weeks)
02 Once-weekly convenient dosing
03 Proven efficacy in obesity, MASH, and Type 2 diabetes
04 62% MASH improvement in clinical trials
Dosing Protocols
Ipamorelin
200-300 mcg per injection / 1-3 times daily depending on goals (1x for longevity, 2-3x for performance)
General Health & Longevity 200mcg 1x daily before bed
Body Composition 250-300mcg 2x daily (morning, pre-workout)
Athletic Performance 200-250mcg 2-3x daily
Sleep & Recovery 200mcg 1x daily 30min before bed
Anti-Aging Protocol 200-250mcg 1-2x daily
Survodutide
0.6mg starting, titrate up to 3.6-6.0mg weekly / Once weekly (same day each week)
Obesity - Conservative Start 0.6mg titrated over 24 weeks Once weekly with 4-week intervals
Obesity - Standard Protocol 3.6-6.0mg Once weekly
MASH Treatment 2.4-4.8mg Once weekly
Type 2 Diabetes 0.3-2.7mg Once weekly
Side Effects
Ipamorelin
Mild hunger increase 20-30 minutes post-injection
Slight drowsiness when taken before bed
Water retention (mild)
Survodutide
Nausea (40-66%)
Diarrhea (25-49%)
Vomiting (15-41%)
Slight heart rate increase (mean 2-5 bpm)
Contraindications
Pregnancy or breastfeeding
Active cancer or history of cancer
Severe kidney or liver disease
Not recommended in pregnancy or breastfeeding
Use contraception during treatment
Research Evidence
Ipamorelin Survodutide
Status Well Studied Extensively Studied
References 5 studies 3 studies
Latest October 2024 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.